New England Journal of Medicine· 2014Q1
Improved Survival with Bevacizumab in Advanced Cervical Cancer
- 1,504citations
- Q1SCImago
- 2014year
Short summary
Adding bevacizumab to chemotherapy in advanced cervical cancer patients increased median overall survival by 3.7 months (17.0 vs. 13.3 months).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Obstetrics and Gynecology
Obstetrics and GynecologyMedicine